OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye DiseaseGlobeNewsWire • 02/28/23
OKYO Pharma appoints leading US ophthalmology expert to its scientific boardProactive Investors • 02/23/23
OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to Its Scientific Advisory BoardGlobeNewsWire • 02/23/23
OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022GlobeNewsWire • 12/30/22
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye DiseaseGlobeNewsWire • 12/22/22
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SECGlobeNewsWire • 12/06/22
OKYO Pharma applies for the go ahead for phase II trial of its dry eye disease treatmentProactive Investors • 11/21/22
OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye DiseaseGlobeNewsWire • 11/21/22
OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye DiseaseGlobeNewsWire • 11/10/22
OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®GlobeNewsWire • 09/08/22
OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)Accesswire • 09/08/22
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharmBusiness Wire • 08/30/22